PolicyEMAMay 12
The European Medicines Agency (EMA) is closely watching an outbreak of Andes hantavirus that started on a cruise ship. Hantavirus is a serious infection spread by infected rodents that can cause severe lung and kidney problems in people. The EMA is working with other European health organizations to monitor the situation and make sure patients get proper treatment.
WHY IT MATTERSIf you or a family member traveled on the affected cruise ship or have symptoms like fever, muscle aches, and difficulty breathing, this outbreak alert helps you understand your potential exposure risk and when to seek medical care.
PolicyEMAMay 12
The European Medicines Agency (EMA) will be closed for a holiday weekend from the evening of May 13 through the morning of May 18, 2026. However, there is still an emergency hotline available if patients need urgent help with medicines during this time.
WHY IT MATTERSIf you're in Europe and need emergency support for a medication during the Ascension Day holiday, you can still reach the EMA's product emergency hotline instead of waiting for the office to reopen.
PolicyEMAMay 12
The European Medicines Agency (EMA) announced that European lawmakers have agreed on a new Critical Medicines Act to make sure important medicines don't run out across Europe. This law was created because Europe has faced medicine shortages in recent years, especially during the COVID-19 pandemic and other global problems. The agreement aims to create stronger and more reliable ways to produce and deliver medicines that people need.
WHY IT MATTERSPatients with rare diseases who depend on specific medicines may experience fewer shortages and more reliable access to their treatments if this act successfully strengthens European medicine supply chains.
PolicyEMAMay 11
The European Medicines Agency has updated its recommendations for which flu virus strains should be included in flu vaccines for the 2026-2027 season. These recommendations apply to different types of flu vaccines, including those made using eggs and live weakened virus versions. The update was announced in May 2026 to help vaccine manufacturers prepare the right vaccines for the upcoming flu season.
WHY IT MATTERSPatients with rare immunodeficiency disorders or chronic conditions that increase flu risk should know which vaccine formulations their doctors may recommend, as the strain composition affects how well the vaccine protects them.
PolicyEMAMay 11
The European Medicines Agency (EMA) created a new advisory group to address vaccine hesitancy—when people are unsure about getting vaccines. The group will meet four times a year and includes doctors, patient representatives, and other experts. Their goal is to help the EMA understand why people distrust vaccines and find ways to rebuild confidence in vaccine safety.
WHY IT MATTERSFor patients with rare diseases who may be immunocompromised or at higher risk from vaccine-preventable infections, vaccine confidence directly affects community protection through herd immunity and the safety of vaccines available to them.
PolicyEMAMay 11
The European Medicines Agency (EMA) has started a new pilot program to help companies develop breakthrough medical devices faster in Europe. This program tests new ways to review and approve devices that could help patients with serious conditions. The goal is to make it easier for innovative medical tools to reach patients who need them.
WHY IT MATTERSThis pilot could speed up access to innovative medical devices for rare disease patients in the EU by streamlining the regulatory review process, though specific diseases and devices in the program have not yet been announced.
PolicyEMAMay 11
The European Medicines Agency (EMA) will be closed on April 27, 2026 for King's Day in the Netherlands and on May 1, 2026 for Labour Day. During these closures, the EMA's regular office services will not be available. Patients and healthcare providers should plan ahead if they need to contact the EMA during these dates.
WHY IT MATTERSIf you're waiting for EMA decisions on a medicine application or orphan drug designation, know that processing may be delayed during these closure dates.
PolicyEMAMay 11
The European Medicines Agency held its monthly safety meeting in May 2026 to review how medicines are being used and whether they're causing any unexpected side effects. The committee looked at new safety concerns and checked on medicines already approved in Europe to make sure they're still safe for patients.
WHY IT MATTERSIf you take a medicine approved in Europe, this committee's work directly affects whether that drug stays on the market or gets new safety warnings added to its label.